We read with profound clinical interest the recent prospective analysis by Ragnarsdottir et al., [1] in the European Journal of Internal Medicine regarding the evolving risk factors for hospital- and community-acquired acute kidney injury. While the authors elegantly emphasize the iatrogenic risks of outpatient pharmacological agents, we believe it is equally imperative to critically address a pervasive inpatient risk factor: the routine administration of prophylactic expansion of extracellular fluid volume for the prevention of contrast-associated acute kidney injury (CA-AKI).
